BioPlus

At a glance

BioPlus filed 25 disclosures in the last 12 months, including 3 5% holder and 2 insider. The most recent key filing was on Oct 8.

Revenue for 2025 was ₩90.9B, up 36.9% on 2024. Operating margin was 16.5% against 35.6% a year earlier. Debt was 46% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩51.9B and operating profit of ₩11.9B.

The 2025 annual report lists 187 employees with an average tenure of 1.7 years and average pay of ₩60.9M, #927 of 1,829 listed companies by average pay. Its 4 directors and auditors were paid ₩177M each on average. It paid ₩70 per common share in cash dividends, against ₩50 a year earlier (+40%). 정현규 and related parties held 29.02% at year end.

From the 2025 annual report

Staff: 187 (108 men, 79 women), of whom 41 on fixed-term contracts. Total pay for the year: ₩10B. Directors and auditors: 4, paid ₩706M in total.

Dividends (common shares)

Largest shareholder

정현규 holds 21.54%; with 4 related parties the group holds 29.02% of common shares at year end (from 29.01% at the start of the year).

Auditor: 우리회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

Financial summary